FDA規制化合物
この化合物はFDA承認または規制されています。有効な処方箋なしでの購入は連邦法違反となる可能性があります。管轄区域のすべての法的要件を確認してください。
Tirzepatide
Mounjaro / Zepbound
Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly, approved as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. It represents a significant advancement over single-agonist GLP-1 drugs like semaglutide, demonstrating superior weight loss and glycemic control in head-to-head trials. The molecule is a 39-amino acid synthetic peptide with a C20 fatty diacid moiety enabling once-weekly dosing through albumin binding.
作用機序
Dual GIP/GLP-1 receptor agonist. Activates both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors simultaneously. Produces greater weight loss and glycemic control than single-receptor agonists.
研究プロトコル
研究目的のみで使用。医療アドバイスではありません。
Research protocols start at 2.5mg weekly for 4 weeks, escalating through 5mg, 7.5mg, 10mg, 12.5mg, to a maximum of 15mg weekly.
研究ノート
Clinical Research Status
Tirzepatide received FDA approval for type 2 diabetes (Mounjaro) in May 2022 and for chronic weight management (Zepbound) in November 2023. The SURMOUNT clinical program demonstrated unprecedented weight loss of up to 22.5% at the highest dose in non-diabetic obese adults. Ongoing trials are investigating applications in heart failure with preserved ejection fraction (HFpEF), obstructive sleep apnea, and MASH/NASH.
Key Published Findings
The SURPASS-2 trial showed tirzepatide 15mg was superior to semaglutide 1mg for both HbA1c reduction (-2.46% vs -1.86%) and weight loss (-12.4kg vs -6.2kg). SURMOUNT-1 demonstrated that 22.5% of participants on the 15mg dose achieved greater than 25% body weight loss at 72 weeks. The SURMOUNT-4 trial confirmed that weight regain occurs upon discontinuation, with participants regaining approximately 14% of lost weight after stopping treatment.
Safety Profile
The most common adverse events are gastrointestinal: nausea (12-33%), diarrhea (12-21%), and vomiting (5-12%), generally mild-to-moderate and decreasing with continued use. A boxed warning exists for thyroid C-cell tumors based on rodent studies, though human relevance is uncertain. Pancreatitis, gallbladder events, and hypoglycemia (when combined with sulfonylureas or insulin) are less common but clinically significant risks.
Drug Interactions & Contraindications
Tirzepatide slows gastric emptying, potentially affecting absorption of oral medications, particularly oral contraceptives (backup contraception recommended for 4 weeks after initiation or dose increase). Contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2 syndrome. Dose adjustments may be needed for insulin and sulfonylureas to prevent hypoglycemia when used in combination.
Comparison to Related Compounds
Head-to-head data from SURPASS-2 shows tirzepatide's superiority over semaglutide for both weight loss and glycemic control, likely attributable to the additive GIP receptor agonism. Unlike semaglutide which is purely a GLP-1 agonist, tirzepatide's dual mechanism may better preserve lean mass during weight loss based on preliminary body composition data. Retatrutide (Eli Lilly's triple agonist adding glucagon receptor activity) represents the next evolution, showing up to 24.2% weight loss in Phase 2 trials.
Community Observations
Available in escalating doses from 2.5mg to 15mg, with recommended titration over 20+ weeks to minimize GI side effects. Supply constraints have been a persistent issue since launch, with many patients experiencing difficulty obtaining prescriptions. Cost without insurance is approximately $1,000-1,100/month, though manufacturer savings programs and compounding pharmacies have expanded access.
半減期
~5 days
再構成
Bacteriostatic water (BAC)
保存
乾燥粉末
Room temperature up to 24 months. Protect from light.
再溶解
Refrigerate 2-8C. Use within 21 days.
米国法的状況
また知られる名前
最新の研究
Highlighting the potential of tirzepatide as a novel dual GIP and GLP-1 receptor agonist for managing type 2 diabetes, focusing on its efficacy and safety profile.
Highlighting the efficacy and safety profile of modern anti-obesity drugs, focusing on liraglutide, semaglutide, and tirzepatide.
Highlighting the latest advancements and considerations for clinicians using GLP-1 receptor agonists and tirzepatide in treating type 2 diabetes and obesity.
よくある質問
Tirzepatideとは何ですか?
Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly, approved as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. It represents a significant advancement over single-agonist GLP-1 drugs like semaglutide, demonstrating superior weight loss and glycemic control in head-to-head trials. The molecule is a 39-amino acid synthetic peptide with a C20 fatty diacid moiety enabling once-weekly dosing through albumin binding.
Tirzepatideはどのように作用しますか?
Dual GIP/GLP-1 receptor agonist. Activates both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors simultaneously. Produces greater weight loss and glycemic control than single-receptor agonists.
Tirzepatideの米国での規制状況は?
FDA-approved (Rx only)
Tirzepatideの半減期は?
~5 days
Tirzepatideの別名は?
Mounjaro, Zepbound
ペプチドコンタクトは、研究目的のみのための要約情報を提供しています。私たちはベンダーの文書をホスト、配布、または推奨していません。すべての分析証明書、GMP認定証明書、およびベンダーコミュニケーションは、購入者によって直接要求され、確認される必要があります。このプラットフォーム上の何らかの情報は法的、医学的、または専門的なアドバイスを構成していません。ユーザーは、適切な法律、州法、および連邦法に準拠するためにベンダー資格を検証し、購入前に遵守することに全責任を持つ必要があります。このプラットフォームを使用することで、完全な個人的責任を承認することになります。
完全な免責事項を読む